{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:51:09Z","timestamp":1790470269008,"version":"4.1.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1001\/jamaoncol.2018.2668","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T14:39:38Z","timestamp":1533220778000},"page":"1382","source":"Crossref","is-referenced-by-count":80,"title":["Modeled Prognostic Subgroups for Survival and Treatment Outcomes in\n                    <i>BRAF<\/i>\n                    V600\u2013Mutated Metastatic Melanoma"],"prefix":"10.1001","volume":"4","author":[{"given":"Axel","family":"Hauschild","sequence":"first","affiliation":[{"name":"University Hospital Schleswig-Holstein, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[{"name":"The Jonsson Comprehensive Cancer Center at University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Dr\u00e9no","sequence":"additional","affiliation":[{"name":"Nantes University, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl D.","family":"Lewis","sequence":"additional","affiliation":[{"name":"University of Colorado Comprehensive Cancer Center, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"McKenna","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhu","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Mun","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant A.","family":"McArthur","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia"},{"name":"University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"26","key":"coi180054r1","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation.","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"coi180054r2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"coi180054r3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1470-2045(14)70301-8","article-title":"Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.","volume":"15","author":"Ribas","year":"2014","journal-title":"Lancet Oncol"},{"issue":"20","key":"coi180054r4","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"coi180054r5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"coi180054r6","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann Oncol"},{"issue":"21","key":"coi180054r8","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1002\/cncr.29586","article-title":"Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.","volume":"121","author":"Menzies","year":"2015","journal-title":"Cancer"},{"issue":"8","key":"coi180054r9","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib.","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi180054r10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.soc.2010.09.007","article-title":"Staging and prognosis of cutaneous melanoma.","volume":"20","author":"Dickson","year":"2011","journal-title":"Surg Oncol Clin N Am"},{"issue":"36","key":"coi180054r11","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification.","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi180054r12","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"coi180054r13","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1158\/1078-0432.CCR-17-0172","article-title":"Gene expression profiling in BRAF-mutated melanoma reveals patient subgroups with poor outcomes to vemurafenib that may be overcome by cobimetinib plus vemurafenib.","volume":"23","author":"Wongchenko","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"coi180054r14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"coi180054r15","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1198\/106186006X133933","article-title":"Unbiased recursive partitioning: a conditional inference framework.","volume":"15","author":"Hothorn","year":"2006","journal-title":"J Comput Graph Stat"},{"key":"coi180054r16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","article-title":"Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.","volume":"82","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"key":"coi180054r17","doi-asserted-by":"publisher","first-page":"v428","DOI":"10.1093\/annonc\/mdx377","article-title":"Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone","volume":"28","author":"Robert","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"coi180054r18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/labinvest.2016.132","article-title":"Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.","volume":"97","author":"Mandal\u00e0","year":"2017","journal-title":"Lab Invest"},{"issue":"3","key":"coi180054r19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade.","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"coi180054r20","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1200\/JCO.2017.35.15_suppl.3057","article-title":"Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): updated safety and clinical activity","volume":"25","author":"Miller","year":"2017","journal-title":"J Clin Oncol"},{"key":"coi180054r21","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2017.35.15_suppl.3063","article-title":"Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): updated safety and clinical activity","volume":"25","author":"Sullivan","year":"2017","journal-title":"J Clin Oncol"},{"key":"coi180054r7","author":"McArthur","year":"2016"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/edhub.ama-assn.org\/journals\/jamaoncology\/fullarticle\/2694878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T12:33:04Z","timestamp":1539261184000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.2668"}},"subtitle":["Pooled Analysis of 4 Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.2668","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}